<DOC>
	<DOC>NCT01828593</DOC>
	<brief_summary>The purpose of the study is to evaluate the effectiveness of the oral nutritional therapy serum-derived bovine immunoglobulin protein isolate (SBI) 2.5 g twice a day (BID) and SBI 5.0 g versus placebo on supporting nutrient absorption in HIV+ subjects with HIV-associated enteropathy.</brief_summary>
	<brief_title>Impact of SBI, a Medical Food, on Nutritional Status in Patients With HIV-associated Enteropathy</brief_title>
	<detailed_description>This study is evaluating the effectiveness of the oral nutritional therapy serum-derived bovine immunoglobulin protein isolate (SBI) 2.5g BID and SBI 5.0g compared to placebo for 6 months on gastrointestinal symptoms, nutritional status and quality of life in HIV+ subjects with HIV-associated enteropathy. In addition, the effects of SBI on pro-inflammatory intestinal microbial populations, bacterial translocation, intestinal barrier function, and systemic immune activation will be investigated.</detailed_description>
	<mesh_term>Intestinal Diseases</mesh_term>
	<mesh_term>HIV Enteropathy</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>History of HIV1 infection Plasma HIV viral load â‰¤40 copies/mL Maintained virologic suppression for 1 year Stable Antiretroviral Therapy (ART) regimen History of HIVassociated diarrhea defined as abnormal passage of 3 or more unformed stools per day or a liquid stool volume greater than 200 g per day for at least 4 weeks duration Positive stool test for pathogenic bacteria, C. difficile or ova and parasites Conditions that require chronic therapy that is known to alter gut microbiota Antibiotics within 2 weeks of screening (exception: prophylaxis antibiotics)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>